ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Inflammation"

  • Abstract Number: 2839 • 2014 ACR/ARHP Annual Meeting

    BCL-2 As a Potential Therapeutic Target in Human Lupus Tubulointerstitial Inflammation

    Kichul Ko1, Denisse Yanez1, Natalya Kaverina1, Vladimir M. Liarski1, Yahui Peng2, Li Lan3, Stuart Perper4, Annette Schwartz5, Liz O'connor6, Andrew Souers7, Steven Elmore7, Lisa Olson5, Maryellen L. Giger3, Li Chun Wang4 and Marcus R. Clark1, 1Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL, 2School of Electronic and Information Engineering, Beijing Jiaotong University, Beijing, China, 3Radiology, University of Chicago, Chicago, IL, 4Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 5AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 6Toxicology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 7AbbVie Inc, North Chicago, IL

    Background/Purpose Lupus nephritis (LuN) is the most common, severe manifestation of systemic lupus erythematosus (SLE). We have previously shown that glomerulonephritis appears to be a…
  • Abstract Number: 1815 • 2014 ACR/ARHP Annual Meeting

    STAT3-Mediated Regulation of Mitochondrial Membrane Potential Is Critical for NLRP3 Inflammasome Activation

    Jehad H. Edwan1, Raphaela Goldbach-Mansky2 and Robert A. Colbert3, 1NIAMS NIH, Bethesda, MD, 2NIAMS, NIH Building 10 Room 6D47B, Bethesda, MD, 3NIAMS/NIH, Bethesda, MD

    Background/Purpose: Self-activating mutations in NLRP3 cause a spectrum of autoinflammatory diseases known as cryopyrin-associated periodic syndromes (CAPS). NLRP3 is a key component of a multiprotein…
  • Abstract Number: 597 • 2014 ACR/ARHP Annual Meeting

    Inflammatory Burden in Recent-Onset Axial Spondyloarthritis

    Juan Jose Aznar Sánchez1, Raul Veroz Gonzalez1, Adela Gallego Flores1, Tamara Libertad Rodriguez Araya1, Piter José Cossio Jimenez2 and Eugenio Chamizo Carmona1, 1Rheumatology, Hospital de Mérida, Mérida, Spain, 2Hospital de Mérida, Mérida, Spain

    Background/Purpose Patients with Non-Radiographic Axial Spondylarthritis (non-Rx AxSpA) don't presnt with different clinical manifestations than patients with Ankilosing Spondylitis (AS), although the inflammatory burden measured…
  • Abstract Number: 2822 • 2014 ACR/ARHP Annual Meeting

    Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis

    Edward C. Keystone1, Peter C. Taylor2, Mark C Genovese3, Douglas E. Schlichting4, Inmaculada De La Torre5, Scott D. Beattie4 and Terence Rooney4, 1University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, 2NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, 3Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, 4Eli Lilly and Company, Indianapolis, IN, 5AVDA. DE LA INDUSTRIA 30, Eli Lilly and Company, Alcobendas, Spain

    Background/Purpose: Baricitinib is an oral inhibitor of JAK1/JAK2 being investigated as a treatment for rheumatoid arthritis (RA).  In a phase 2b study, baricitinib treatment resulted…
  • Abstract Number: 1812 • 2014 ACR/ARHP Annual Meeting

    Investigation of the Sting/Interferon Pathway Activation in a Novel Vasculopathy and Pulmonary Syndrome

    Yin Liu1, Adriana Almeida de Jesus2,3, Bernadette Marrero4, Dan Yang5, Gina A. Montealegre Sanchez6, Steve Brooks7, Zuoming Deng8, Amy Paller9, Manfred Boehm5 and Raphaela Goldbach-Mansky6, 1Translational Autoinflammatory Disease Section, Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, 2Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 3Translational Autoinflammatory Diseases Section, NIAMS/NIH, Bethesda, MD, 4Translational Autoinflammatory Disease Section, NIAMS/NIH, Bethesda, MD, 5Laboratory of Cardiovascular Regenerative Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 6Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 7NIAMS/NIH, Bethesda, MD, 8Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 9Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose:  We have recently studied a group of patients with a prominent interferon (IFN) signature in the blood, distinct from IL-1 mediated autoinflammatory diseases. Six…
  • Abstract Number: 405 • 2014 ACR/ARHP Annual Meeting

    14-3-3η: A Mechanistic Biomarker That Supports the Concept of “Uncoupling” of Inflammation and Joint Damage

    Dirkjan van Schaardenburg1, Mairead Murphy2, Yuan Gui2, Samina Turk3, Walter P. Maksymowych4, Kelly Young5 and Anthony Marotta6, 1Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, 2Augurex Life Sciences Corp., North Vancouver, BC, Canada, 3Reade, Amsterdam, Netherlands, 4Medicine, University of Alberta, Edmonton, AB, Canada, 5Rheumatoid Patient Foundation, Cocoa, FL, 61423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada

    Background/Purpose In RA, irreversible joint damage often begins within the first year of symptom onset. A compelling and growing body of data describing the "uncoupling"…
  • Abstract Number: 2792 • 2014 ACR/ARHP Annual Meeting

    Methotrexate Prevents Inflammatory Osteolysis By Activation of the Adenosine a2A Receptor (A2AR)

    Aranzazu Mediero1, Tuere Wilder2 and Bruce N. Cronstein3, 1Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, 2Medicine, division of Translational Medicine, NYU School of Medicine, New York, NY, 3NYU School of Medicine, Division of Rheumatology, New York, NY

    Background/Purpose Prior studies demonstrate that adenosine, acting at A2AR, mediates the anti-inflammatory effects of methotrexate (MTX) in models of both acute and chronic inflammation. We…
  • Abstract Number: 1723 • 2014 ACR/ARHP Annual Meeting

    Identification of the Microbiome As a Potential Trigger of Systemic Sclerosis By Metagenomic RNA-Sequencing of Skin Biopsies

    Michael Johnson1, Zhenghui Li1, Michelle Dimon2, Tammara A. Wood1, Robert Lafyatis3, Sarah Arron2 and Michael Whitfield4, 1Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, 2Dermatology, University of California, San Francisco, San Francisco, CA, 3Arthritis Center, Boston University, Boston, MA, 4Geisel School of Medicine at Dartmouth, Hanover, NH

    Background/Purpose:    Systemic sclerosis (SSc) is a rare and poorly understood systemic autoimmune disease that results in skin fibrosis and severe internal organ involvement. There…
  • Abstract Number: 344 • 2014 ACR/ARHP Annual Meeting

    Reduced Macrophages in the Synovium Contribute to the Effective Treatment of Spontanneous Arthritis Observeded in Human TNF-Transgenic Mice

    Robert Birkett1, Qi Quan Huang1, Bo Shi2 and Richard Pope3, 1Medicine/Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, 2Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, 3Medicine/Rheumatology Div, Northwestern University Feinberg school of Medicine, Chicago, IL

    Background/Purpose Macrophages in rheumatoid arthritis (RA) synovial tissue (ST) produce high levels of inflammatory cytokines/chemokines and exhibit enhanced differentiation into osteoclasts in the pannus, playing…
  • Abstract Number: 2433 • 2014 ACR/ARHP Annual Meeting

    Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac for Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

    Fabiola Atzeni1,2, Alessandra Monguzzi3, Elisabetta Grillo3, Luigi Lanata3 and Piercarlo Sarzi-Puttini2, 1V Giovanni Battista Grassi 74, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, 2Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, 3Medical Department, Dompé SpA, Milan, Italy

    Background/Purpose: Patients with rheumatic diseases, including rheumatoid arthritis (RA), describe symptoms such as pain and stiffness as important factors affecting their quality of life. The…
  • Abstract Number: 1643 • 2014 ACR/ARHP Annual Meeting

    Role of Inflammasome Activation in Systemic Lupus Erthematosus: Are Innate Immune Cells Activated?

    Rodolfo Perez Alamino1, Raquel Cuchacovich2, Arnold Zea3 and Luis R. Espinoza4, 1internal Medicine, LSUHSC, New Orleans, LA, 2Rheumatology, LSU Medical Center, New Orleans, LA, 3Stanley Scott Cancer Center, New Orleans, LA, 4Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA

    Background/Purpose Systemic lupus erythematosus (SLE) presents with a wide spectrum of clinical and immunologic abnormalities. On the other hand, exciting data is emerging about the…
  • Abstract Number: 35 • 2014 ACR/ARHP Annual Meeting

    Hydrogen Sulfide Inhibits Human Osteoclast Differentiation in Vitro By Triggering Sustained Antioxidant Response and Inhibiting the RANKL/OPG Ratio

    Francesco Grassi1, Laura Gambari2, Andrea Facchini3 and Gina Lisignoli4, 1LAB. RAMSES, ISTITUTO ORTOPEDICO RIZZOLI, BOLOGNA, Italy, 2Lab. RAMSES, ISTITUTO ORTOPEDICO RIZZOLI, BOLOGNA, Italy, 3Lab of Immunorheumatology and Tissue Regeneration, ISTITUTO ORTOPEDICO RIZZOLI, BOLOGNA, Italy, 4LAB. OF IMMUNORHEUMATOLOGY AND TISSUE REGENERATION, ISTITUTO ORTOPEDICO RIZZOLI, BOLOGNA, Italy

    Background/Purpose Hydrogen sulfide (H2S) has been recently appreciated as a novel gasotransmitter with an important role in the regulation of tissues and organs. H2S is…
  • Abstract Number: 2451 • 2014 ACR/ARHP Annual Meeting

    Mir-155 Expression Correlates with Clinical Disease Activity and Has Effector Function in Rheumatoid Arthritis

    Aziza Elmesmari1, Derek G. Gilchrist2, Mariola Kurowska-Stolarska3 and Iain B. McInnes4, 1Immunology, Institute of Infection,Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 2Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 3Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 4Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: MicroRNAs are fine tuners of biological pathways that function via post-transcriptional regulation of target mRNA life span.  MicroRNA 155 (miR155) is particularly implicated in…
  • Abstract Number: 1516 • 2014 ACR/ARHP Annual Meeting

    TNF-Alpha Inhibitors Normalizes Melanocortin Receptor Subtype 2, 3 and 4 Expression in CD8+, CD14+ and CD19+ Leukocyte Subsets in Rheumatoid Arthritis

    Marlene Andersen1, Michael Kruse Meyer2, Ivan Nagaev3, Olga Nagaeva3, Jarl E.S. Wikberg4, Lucia Mincheva-Nilsson3 and Grethe N. Andersen2, 1Department of Rheumatology, Aalborg University, Hjørring, Denmark, 2Clinic of Rheumatology, Hospital of Vendsyssel/Aalborg University, Hjørring, Denmark, 3Department of Clinical Immunology, University of Umeå, Umeå, Sweden, 4Department of Pharmaceutical Biosciences, Department of Pharmaceutical Pharmacology, Uppsala, Sweden

    Background/Purpose: We examined Adalimumab´s effects on melanocortin receptor subtype (MC)1-5 gene expression in important leukocyte subsets in rheumatoid arthritis (RA). The melanocortin system is a…
  • Abstract Number: 33 • 2014 ACR/ARHP Annual Meeting

    Stimulation of the Adenosine a2A receptor (A2AR) Regulates the Expression of Netrin1 and Their Receptors (Unc5b, DCC) and Inhibits Osteoclast Differentiation and Inflammatory Bone Destruction

    Aranzazu Mediero1, Bhama Ramkhelawon2, Miguel Perez-Aso3, Kathryn Moore2 and Bruce N. Cronstein4, 1Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, 2Leon H. Charney Division of Cardiology, Department of Medicine,, NYU School of Medicine, New York, NY, 3545 1st Ave., New York University, New York City, NY, 4NYU School of Medicine, Division of Rheumatology, New York, NY

    Background/Purpose A variety of molecules mediate communication between osteoclasts and osteoblasts during bone remodeling. Netrin1 is a member of the family of axonal guidance proteins,…
  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 58
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology